Cervical epidural hematoma with hemiparesis: An unusual but important stroke mimic

payt.helady61 shared this article with you from Inoreader Cervical epidural hematoma with hemiparesis: An unusual but important stroke mimic Via American Journal of Physical Medicine & Rehabilitation - Published Ahead-of-Print No abstract available View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Effectiveness of Botulinum Toxin A injection in managing mobility related outcomes in adult patients with cerebral palsy – systematic review

payt.helady61 shared this article with you from Inoreader Effectiveness of Botulinum Toxin A injection in managing mobility related outcomes in adult patients with cerebral palsy – systematic review Via American Journal of Physical Medicine & Rehabilitation - Published Ahead-of-Print Purpose Intramuscular Botulinum toxin A (BTX-A) is used in the management of focal spasticity in cerebral palsy (CP). We aimed to conduct a systematic review to assess current literature on the use of BTX-A in the management of mobility related outcomes among adult persons with spastic CP. Methods All studies reporting on the use of BTX-A in the management of spastic CP among adult persons were identified by searching the following electronic databases: PubMed, CINAHL, the Cochrane Library, and EMBASE. Results Six studies were included in the review. Most studies were conducted in mixed patient groups comprising patients with movement disorders, traumatic brain injury, cerebral palsy and other disorders requiring therapy for spasticity. BTX-A was shown to be effective in improving spasticity related outcomes among persons with CP but mixed results were shown for functional outcomes. Conclusions More studies are required on exclusive CP cohorts using recommended and currently used scales, incorporating Quality of life and patient satisfaction scales. Results from long term follow up studies will be valuable for better evaluation of the effectiveness of BTX-A in the management of spasticity related outcomes among adult persons with CP. Correspondence: Dr. Nalinda Andraweera, Department of Rehabilitation Medicine, Modbury Public Hospital, Smart Road, Modbury, South Australia, Australia; phone +61 8 8161 2000, email Nalinda.andraweera@sa.health.gov.au Conflicts of interest: The authors declare no conflicts of interest Funding: No funding was received Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Physical Function in Stem Cell Transplant Patients Undergoing Corticosteroid Treatment for Acute Graft-Versus-Host-Disease

payt.helady61 shared this article with you from Inoreader An Exploratory Study on Physical Function in Stem Cell Transplant Patients Undergoing Corticosteroid Treatment for Acute Graft-Versus-Host-Disease Via American Journal of Physical Medicine & Rehabilitation - Published Ahead-of-Print Acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplant (SCT) is treated with corticosteroids, placing patients at risk for steroid myopathy. In this single-arm cohort study, 23 patients who were started on high-dose corticosteroids for aGVHD underwent a series of functional tests (baseline, Day 14, 28, 56): six-minute walk test (6MWT), hip flexors (HF) and knee extensors (KE) strength via dynamometry, five times sit-to-stand (5xSTS), Brooke scale for myopathy, modified Adult Myopathy Assessment Tool (AMAT), and manual muscle testing (MMT). Participants were prescribed home exercises including walking and resistance exercises, with low adherence. Fifteen (63%) participants were male and median (range) age 60 (36-70) years old. Median (range) corticostero id duration and cumulative equivalent methylprednisolone dose were 66 (22-165) days and 3625 (1020-11720) milligrams, respectively. At Day 14, there was a significant decline in 5xSTS (P=.0132), KE (P=.0182), and MMT (P=.0466). Functional tests negatively-associated with cumulative corticosteroid dose included: 6MWT distance (P=.0103), HF strength (P=.0262), KE strength (P=.0369), manual muscle testing strength (P=.0319). 5xSTS was positively associated with corticosteroid dose (P=.0003). In conclusion, SCT patients receiving high-dose corticosteroids for aGVHD are at risk for weakness detected as early as Day 14. Increasing adherence to exercise may mitigate these changes. *Currently at Baylor College of Medicine, Houston, TX; but work for this study was conducted at University of Texas MD Anderson Cancer Center Corresponding author: An Ngo-Huang, DO, Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1414, Houston, TX 77030; Tel: 713-745-2327; Fax: 713-792-6092; E-mail: ango2@mdanderson.org Disclosure of Conflicts of Interest: The authors declare no competing financial interests. This was an unfunded study. Results from this study were presented at the 2018 American Congress of Rehabilitation Medicine Annual Meeting as a poster presentation: Ngo-Huang A, Yadav R, Bansal S, Williams J, Liu D, Wu J, Alousi A, Fu JB, Bruera E. Changes in Physical Function in Stem Cell Transplant Patients at Risk for Steroid Myopathy. Archives of Physical Medicine and Rehabilitation 99(12):E194, 12/2018. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis

payt.helady61 shared this article with you from Inoreader Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis Via Antimicrobial Resistance and Infection Control - Latest Articles Owing to their resistance to an important class of antibiotics, the prevention and treatment of carbapenem-resistant (CR)/non-susceptible Gram-negative (GN) infections has become an important public health obj... View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Impact of a multifaceted intervention to improve antibiotic prescribing: a pragmatic cluster-randomised controlled trial

payt.helady61 shared this article with you from Inoreader Impact of a multifaceted intervention to improve antibiotic prescribing: a pragmatic cluster-randomised controlled trial Via Antimicrobial Resistance and Infection Control - Latest Articles This study sought to assess the effectiveness and return on investment (ROI) of a multifaceted intervention aimed at improving antibiotic prescribing for acute respiratory infections in primary care. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression

payt.helady61 shared this article with you from Inoreader Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression Via BMC Complementary and Alternative Medicine - Latest Articles The currently available treatments for colorectal cancer (CRC) are often associated with serious side-effects. Therefore, the development of a novel nutraceutical agent may provide an alternative complementary... View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

PmDNE: Prediction of miRNA-Disease Association Based on Network Embedding and Network Similarity Analysis

payt.helady61 shared this article with you from Inoreader PmDNE: Prediction of miRNA-Disease Association Based on Network Embedding and Network Similarity Analysis Via BioMed Research International Successful prediction of miRNA-disease association is nontrivial for the diagnosis and prognosis of genetic diseases. There are many methods to predict miRNA and disease, but biological data are numerous and complex, and they often exist in the form of network. How to accurately use the features of miRNA and disease-related biological networks to predict unknown association has always been a challenge. Here, we propose PmDNE, a method based on network embedding and network similarity analysis, to predict the miRNA-disease association. In PmDNE, the structure of network bipartite graph is improved, and a random walk generator is designed. For embedded vectors, 128 dimensions are used, and the accuracy of prediction is significantly improved. Compared with other network embedding methods, PmDNE is comparable and competitive with the state of art methods. Our method can solve the problem of feature extraction, reduce the dimension of features, and improve the efficiency of miRNA-disease association prediction. This method can also be extended to other area for biomedical network prediction. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Anti-Inflammatory Effects of Heritiera littoralis Fruits on Dextran Sulfate Sodium- (DSS-) Induced Ulcerative Colitis in Mice by Regulating Gut Microbiota and Suppressing NF-κB Pathway

payt.helady61 shared this article with you from Inoreader Anti-Inflammatory Effects of Heritiera littoralis Fruits on Dextran Sulfate Sodium- (DSS-) Induced Ulcerative Colitis in Mice by Regulating Gut Microbiota and Suppressing NF-κB Pathway Via BioMed Research International Aim of the Study. This study is aimed at exploring the effects and pharmacological mechanisms of the extracts from the Heritiera littoralis fruit (EFH) on dextran sulfate sodium- (DSS-) induced ulcerative colitis (UC) in mice. Materials and Methods. The chemical compositions of EFH were identified using LC-ESI-MS. The mice with 3% DSS-induced UC were administered EFH (200, 400, and 800 mg/kg), sulfasalazine (SASP, 200 mg/kg), and azathioprine (AZA, 13 mg/kg) for 10 days via daily gavage. The colonic inflammation was evaluated by the disease activity index (DAI), colonic length, histological scores, and levels of inflammatory mediators. The gut microbiota was characterized by 16S rRNA gene sequencing and analysis. Results. LC-ESI-MS analysis showed that EFH was rich in alkaloids and flavones. The resu lts indicated that EFH significantly improved the DAI score, relieved colon shortening, and repaired pathological colonic variations in colitis. In addition, proteins in the NF-κB pathway were significantly inhibited by EFH. Furthermore, EFH recovered the diversity and balance of the gut microbiota. Conclusions. EFH has protective effects against DSS-induced colitis by keeping the balance of the gut microbiota and suppressing the NF-κB pathway. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

AImipenem and Relebactam : Single- and Multiple-Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of

payt.helady61 shared this article with you from Inoreader A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants [Pharmacology] Via AAC Accepts: Articles Published Ahead of Print Relebactam/imipenem/cilastatin is approved in the US to treat complicated urinary tract and intra-abdominal infections in patients that have limited or no alternative treatment options and HABP/VABP. Initial pharmacokinetic, safety, and tolerability studies of relebactam with and without imipenem/cilastatin included mostly Caucasian participants. This study evaluated pharmacokinetics, safety, and tolerability of relebactam/imipenem/cilastatin in 12 healthy Chinese participants after three single doses of increasing concen tration (relebactam 125, 250, or 500 mg/cilastatin 250, 500, or 1000 mg/imipenem 250, 500, or 1000 mg) and after multiple doses every 6 h of a single concentration (relebactam 250 mg/cilastatin 500 mg/imipenem 500 mg) for 14 days. After single doses, area under the concentration–time curve (AUC) extrapolated to infinity (relebactam, 15.0–70.7 h*mg/liter; imipenem, 24.1–109.8 h*mg/liter; cilastatin, 18.4–95.3 h*mg/liter) and AUC from 0–6 h (relebactam, 14.2–66.3 h*mg/liter; imipenem, 23.4–107.3 h*mg/liter; cilastatin, 18.3–94.4 h*mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9–8.3 liters/h; imipenem, 8.6–10.4 liters/h; cilastatin, 10.5–13.6 liters/h) and half-life (relebactam, 1.4–1.6 h; imipenem, 1.0–1.2 h; cilastatin, 0.7–1.0 h) were consistent between doses. Pharmacokinetic parameters after multiple doses were similar to parameters after a single dose (geometric mean ratios of 0.8–1.0 for all three agents). Relebactam/imipen em/cilastatin was well tolerated; mild adverse events occurred during single dosing, and one participant experienced serious adverse events after multiple doses. Pharmacokinetics and safety data are comparable with data from participants of other ethnicities, supporting the use of relebactam/imipenem/cilastatin at the approved dose and schedule in Chinese patients. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes [Antiviral Agents]

payt.helady61 shared this article with you from Inoreader Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes [Antiviral Agents] Via AAC Accepts: Articles Published Ahead of Print Lenacapavir (LEN, GS-6207) is a potent, first-in-class inhibitor of HIV-1 capsid with long-acting properties and the potential for subcutaneous dosing every 3 months or longer. In the clinic, a single subcutaneous LEN injection (20 mg to 750 mg) in people-living-with-HIV (PLWH) showed a strong antiviral response, with a >2.3 mean log10 decrease in HIV-1 RNA at day 10. HIV-1 Gag mutations near protease (PR) cleavage sites have emerged with the use of protease inhibitors (PIs). Here we have characterized the a ctivity of LEN in mutants with Gag cleavage site mutations (GCSMs), and mutants resistant to other drug classes. HIV mutations were inserted into the pXXLAI clone and the resulting mutants (n = 70) were evaluated using a 5-day antiviral assay. LEN EC50 fold change versus wild-type ranged from 0.4 to 1.9 in these mutants, similar to the control drug. In contrast, reduced susceptibility to PIs and maturation inhibitors (MIs) was observed. Testing of isolates with resistance against the 4 main classes of drugs (n = 40) indicated wild-type susceptibility to LEN (fold change ranging from 0.3 to 1.1), while reduced susceptibility was observed for control drugs. HIV GCSMs did not impact the activity of LEN, while some conferred resistance to MIs and PIs. Similarly, LEN activity was not affected by naturally-occurring variations in HIV Gag, in contrast to the reduced susceptibility observed for MIs. Finally, the activity of LEN was not affected by the presence of re sistance mutations to the 4 main ARV classes. These data support the evaluation of LEN in PLWH with multi-class resistance. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19 [Letters]

payt.helady61 shared this article with you from Inoreader Favipiravir and the Need for Early Ambulatory Treatment of COVID-19 [Letters] Via AAC Accepts: Articles Published Ahead of Print The commentary by McCullough emphasizes the urgent need for early ambulatory therapy of COVID-19 (1).... View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Omadacycline against Nontuberculous Mycobacteria

payt.helady61 shared this article with you from Inoreader In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria (NTM) [Susceptibility] Via AAC Accepts: Articles Published Ahead of Print Nontuberculous mycobacteria (NTM) infections are increasing globally. Mycobacterium avium complex (MAC) and M. abscessus complex are the most frequently encountered NTM and oral treatment options are extremely limited for these pathogens, especially for the M. abscessus complex. In this study, the in vitro potency of omadacycline, a new tetracycline derivative, was tested against 111 isolates of NTM. MIC testing was performed as recommended by the Clinical and Laboratory Standards Institute aga inst 70 isolates of rapidly growing mycobacteria (RGM) of which >90% were tetracycline resistant. These included M. abscessus subsp. abscessus (20), M. abscessus subsp. massiliense (3), M. chelonae (15), M. immunogenum (7), the M. fortuitum group including six doxycycline resistant isolates (12), and the M. mucogenicum group including four doxycycline resistant isolates (10). Forty-one isolates of slowly growing mycobacteria (SGM) species including 16 isolates of MAC were also tested. Omadacycline was active against all RGM species with an MIC50 range of 0.004-0.25 and 0.06-1 μg/ml for 80% and 100% inhibition, respectively. For M. abscessus subsp. abscessus, MIC50 values were 0.06 and 0.12 μg/ml with 80% and 100% inhibition respectively. There was considerable trailing of the omadacycline endpoint with the RGM. MICs for tigecycline exhibited no trailing and were generally within 1-2 dilu tions of the 100% inhibition omadacycline MIC values. While there was no trailing observed in SGM, omadacycline MICs were higher (MIC range 8->16 μg/ml, N = 41) as previously noted with tigecycline. This study supports further research of omadacycline including clinical trials for the treatment of RGM infections, especially M. abscessus. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.